WuXi Biologics' Singapore CRDMO Center Modular Biological API Production Plant Breaks Ground
Innovative modular design will accelerate construction and production progress, achieving flexible switching for various product types.
The completed project will become one of the world's largest modular biological API (DP) production plants, further solidifying WuXi Biologics' leading position in the biologics end-to-end production services industry.
Singapore, July 29, 2025 /PR Newswire/ -- Leading contract research, development and manufacturing (CRDMO) service company WuXi Biologics (2269.HK) announced that its Singapore CRDMO center's modular biological API production plant has broken ground. Under the strategic cooperation with Pharmadule Morimatsu, 470 main modules are being manufactured at Pharmadule Morimatsu's Changshu factory and will be transported to Singapore's Biopharmaceutical Park for installation. The project is expected to cover an area of approximately 30,000 square meters upon completion.
The modular biological API production plant will be equipped with advanced production lines, quality control (QC) center laboratories supporting comprehensive release and stability testing, as well as manufacturing science and technology (MSAT) laboratories, significantly enhancing the company's end-to-end biologics services capabilities. The plant will feature three pre-filled syringe (PFS) production lines and two lyophilized powder and liquid filling lines, providing one-stop-shop biologics production services covering clinical and commercial stages for various product types. WuXi Biologics is committed to sustainable development and the plant will adopt green technologies such as solar power and advanced energy monitoring and analysis systems, with an expected operational date of 2027.
Additionally, WuXi Biologics' Singapore CRDMO center's modular drug substance (DS) production plant has entered the design phase.
WuXi Biologics CEO Dr. Chris Wang said: "The increasing diversification of global biopharmaceutical pipelines and advancements in biological manufacturing technologies drive the industry to build more innovative, flexible, and efficient production facilities to meet dynamic market demands. We are thrilled to collaborate with Pharmadule Morimatsu to advance the construction of our Singapore CRDMO center's modular biological API production plant, accelerating project progress." Through continuous expansion of global capacity and strengthening technical capabilities, we remain committed to empowering clients to achieve innovative breakthroughs and making high-quality biologics available to more patients worldwide."
WuXi Biologics provides end-to-end one-stop-shop biologics services through its five research centers, eight development centers, and eight production centers (including nine operational API production plants and 16 DS production plants). The company's advanced API production plants can develop, fill, label, and package liquid or lyophilized APIs for biopharmaceuticals, vaccines, excipients, and injectables.
Leveraging its production bases in Ireland, Germany, the United States, Singapore, and China, with a total planned capacity of over 500 million liters, WuXi Biologics offers high-efficiency, reliable, and quality services to global clients. The company's dual-site manufacturing strategy ensures that raw materials can be sourced and products produced in different regions, effectively enhancing supply chain resilience and operational flexibility.